Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Edotecarin.

William A Denny1

  • 1The University of Auckland, Auckland Cancer Society Research Centre, School of Medical Sciences, Private Bag 92019, Auckland, New Zealand. b.denny@auckland.ac.nz

Idrugs : the Investigational Drugs Journal
|April 2, 2004
PubMed
Summary
This summary is machine-generated.

Banyu Pharmaceutical and Pfizer are developing edotecarin, a novel topoisomerase I inhibitor, for treating solid tumors. This drug shows potential in cancer therapy research.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation.

European journal of medicinal chemistry·2026
Same author

Advancing the antituberculosis activity of nitropicolinic acids and amides.

European journal of medicinal chemistry·2025
Same author

Development of fatty acid analogues with potent anabolic effects on bone in male mice.

Bone reports·2025
Same author

ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding.

The Biochemical journal·2024
Same author

Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate.

Cell communication and signaling : CCS·2024
Same author

Retraction: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation.

Cancer research·2023
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Solid tumors represent a significant global health challenge.
  • Targeting DNA-related enzymes like topoisomerase I is a validated strategy in cancer treatment.

Purpose of the Study:

  • To introduce edotecarin, an indolocarbazole derivative.
  • To highlight its mechanism as a topoisomerase I inhibitor.
  • To present its development for solid tumor treatment.

Main Methods:

  • Drug development pipeline analysis.
  • Pharmacological profiling of topoisomerase I inhibitors.
  • Preclinical and clinical trial assessments (details not provided in abstract).

Main Results:

  • Edotecarin is identified as a potent topoisomerase I inhibitor.
  • Development is ongoing for potential solid tumor applications.

Conclusions:

  • Edotecarin is a promising candidate for solid tumor therapy.
  • Further research and clinical trials are warranted to establish its efficacy and safety.